Total Funding
71
64
Total FundingVenture - Series Unknown raised
Growth Score 71 in past quarter
-4 pts
Heat Score 64 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
91375
Zero Point Five Therapeutics develops drugs to treat soil-transmitted helminthiasis.
- Joseph Amprey: CEO and FounderPast Role: Symbiomix Therapeutics, CBO & Co-Founder
About the Company
Zero Point Five Therapeutics develops drugs to treat soil-transmitted helminthiasis. A pharmaceutical company is developing a single-dose formulation for soil-transmitted helminthiasis (STH). STH is a disease that primarily affects poor rural communities of color with inadequate sewage systems.